Outcomes With Different Administration Schedules of Bortezomib in Bortezomib, Lenalidomide, and Dexamethasone as First-Line Therapy in Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes With Different Administration Schedules of Bortezomib in Bortezomib, Lenalidomide and Dexamethasone (VRd) as First-Line Therapy in Multiple Myeloma
Am. J. Hematol 2020 Dec 16;[EPub Ahead of Print], J Cook, I Johnson, A Higgins, S Sidana, R Warsame, W Gonsalves, MA Gertz, F Buadi, M Lacy, P Kapoor, A Dispenzieri, T Kourelis, D Dingli, PA Amie Fonder, S Hayman, M Hobbs, YL Hwa, R Kyle, N Leung, R Go, VS Rajkumar, S KumarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.